Kristen Sikorski, MD
Allergy & Immunology · Skillman, NJNPI 1194722991
Payments from drug & device makers
Across 839 payments — averaging $52.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$19K
- Teva Pharmaceuticals USA, Inc.$11K
- AstraZeneca$5K
- GSK$4K
- Sanofi$847
- Novartis$638
- plus $4K from 27 others
What the payments were for
- Speaking & faculty fees$26,86061%
- Travel & lodging$2341%
- Food & beverage$16,52238%
- Education$3191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 137 | $18,807 |
| Teva Pharmaceuticals USA, Inc. | 72 | $11,047 |
| AstraZeneca | 169 | $5,236 |
| GSK | 171 | $3,516 |
| Sanofi | 47 | $847 |
| Novartis | 42 | $638 |
| LEO Pharma Inc. | 24 | $615 |
| Regeneron Healthcare Solutions, Inc. | 21 | $461 |
| CSL Behring | 22 | $362 |
| ARS Pharmaceuticals Operations, Inc. | 17 | $272 |
| Sanofi-aventis U.S. LLC | 3 | $261 |
| Amgen | 15 | $243 |
| Kaleo, Inc. | 15 | $209 |
| Genentech USA, Inc. | 15 | $193 |
| Covis Pharma GmbH | 12 | $166 |
| Insmed, Inc. | 3 | $146 |
| Blueprint Medicines Corporation | 8 | $125 |
| Pfizer | 7 | $108 |
| AbbVie | 1 | $102 |
| Hikma Pharmaceuticals USA | 6 | $93 |
| Incyte Corporation | 5 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $88 |
| Alk-abello, Inc | 5 | $64 |
| Boehringer Ingelheim | 4 | $61 |
| Merck | 3 | $39 |
| Biocryst US Sales Co., LLC | 2 | $36 |
| Organon | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Octapharma USA, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Greer Laboratories, Inc. | 1 | $14 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xhance$17,443
- AirDuo RespiClick$10,498
- ProAir Digihaler$10,498
- ArmonAir Digihaler$10,498
- FASENRA$1,792
- TEZSPIRE$1,298
- NUCALA$763
- AIRSUPRA$698
- BREZTRI$536
- FARXIGA$412
- TRELEGY ELLIPTA$349
- DUPIXENT$335
- Brinsupri$253
- ANZUPGO$236
- SYMBICORT$124
- QULIPTA$102
- UBRELVY$102
How this compares
$43,936 in reported general payments places this provider in the 80th percentile of 135 allergy & immunology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $45,543 |
| XolairOmalizumab | 13 | $36,038 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $24,305 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $19,658 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $5,404 |
| Arnuity ElliptaFluticasone Furoate | 22 | $4,368 |
| Epinephrine | 18 | $4,149 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,965 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 14 | $3,426 |
| Mometasone Furoate | 30 | $2,853 |
| Ipratropium Bromide | 39 | $2,568 |
| Montelukast Sodium | 120 | $1,778 |
| Azelastine Hcl | 25 | $1,198 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,078 |
| Clobetasol Propionate | 20 | $1,047 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $3,516 | $69,56996 claims |
| Hikma Pharmaceuticals USAEpinephrine | $93 | $4,14918 claims |
| AstraZenecaSymbicort | $5,236 | $3,96515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 135 allergy & immunology providers in New Jersey.
Other allergy & immunology in Skillman
- Andrew PedinoffSkillman$2.3M
- Helen SkolnickSkillman$85K
- Darrell SouthernSkillman$5K
- Ellen SherOcean$2.7M
- Bruce DecotiisBrick$647K
- Patrick PerinTeaneck$589K
- Peter RickettiTrenton$501K
- Jinping GuoMarlton$488K
- Mark WeinsteinBelleville$424K
- Tina ZeccaLittle Silver$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.